|
US4711955A
(en)
|
1981-04-17 |
1987-12-08 |
Yale University |
Modified nucleotides and methods of preparing and using same
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US5599720A
(en)
|
1982-08-27 |
1997-02-04 |
Multilyte Limited |
Measurement of analyte concentration
|
|
US4737453A
(en)
|
1984-12-12 |
1988-04-12 |
Immunomedics, Inc. |
Sandwich immunoassay utilizing a separation specific binding substance
|
|
US4752566A
(en)
|
1985-12-17 |
1988-06-21 |
Genetics Institute, Inc. |
Displacement polynucleotide method and reagent complex employing labeled probe polynucleotide
|
|
EP0527818A4
(en)
*
|
1990-04-30 |
1993-09-15 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide modulation of arachidonic acid metabolism
|
|
US5849479A
(en)
|
1990-06-11 |
1998-12-15 |
Nexstar Pharmaceuticals, Inc. |
High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
|
|
US6124449A
(en)
|
1990-06-11 |
2000-09-26 |
Nexstar Pharmaceuticals, Inc. |
High affinity TGFβ nucleic acid ligands and inhibitors
|
|
US5660985A
(en)
|
1990-06-11 |
1997-08-26 |
Nexstar Pharmaceuticals, Inc. |
High affinity nucleic acid ligands containing modified nucleotides
|
|
US5580737A
(en)
|
1990-06-11 |
1996-12-03 |
Nexstar Pharmaceuticals, Inc. |
High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
|
|
US5811533A
(en)
|
1990-06-11 |
1998-09-22 |
Nexstar Pharmaceuticals, Inc. |
High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
|
|
US5674685A
(en)
|
1990-06-11 |
1997-10-07 |
Nexstar Pharmaceuticals, Inc. |
High affinity PDGF nucleic acid ligands
|
|
US5874218A
(en)
|
1990-06-11 |
1999-02-23 |
Nexstar Pharmaceuticals, Inc. |
Method for detecting a target compound in a substance using a nucleic acid ligand
|
|
US5731144A
(en)
|
1990-06-11 |
1998-03-24 |
Nexstar Pharmaceuticals, Inc. |
High affinity TGFβ nucleic acid ligands
|
|
US5731424A
(en)
|
1990-06-11 |
1998-03-24 |
Nexstar Pharmaceuticals, Inc. |
High affinity TGFβ nucleic acid ligands and inhibitors
|
|
ATE318832T1
(de)
|
1990-06-11 |
2006-03-15 |
Gilead Sciences Inc |
Verfahren zur vervendung von nukleinsäureliganden
|
|
US5705337A
(en)
|
1990-06-11 |
1998-01-06 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: chemi-SELEX
|
|
US5270163A
(en)
|
1990-06-11 |
1993-12-14 |
University Research Corporation |
Methods for identifying nucleic acid ligands
|
|
DK0515660T3
(da)
*
|
1990-12-21 |
1997-07-28 |
Hoffmann La Roche |
HLA-DQbeta-DNA-typebestemmelse
|
|
US5840867A
(en)
|
1991-02-21 |
1998-11-24 |
Gilead Sciences, Inc. |
Aptamer analogs specific for biomolecules
|
|
US6762290B1
(en)
|
1999-07-29 |
2004-07-13 |
Gilead Sciences, Inc. |
High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
|
|
US5582981A
(en)
|
1991-08-14 |
1996-12-10 |
Gilead Sciences, Inc. |
Method for identifying an oligonucleotide aptamer specific for a target
|
|
US5412087A
(en)
|
1992-04-24 |
1995-05-02 |
Affymax Technologies N.V. |
Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
|
|
US5580972A
(en)
|
1993-06-14 |
1996-12-03 |
Nexstar Pharmaceuticals, Inc. |
Purine nucleoside modifications by palladium catalyzed methods
|
|
US5719273A
(en)
|
1993-06-14 |
1998-02-17 |
Nexstar Pharmaceuticals, Inc. |
Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
|
|
DE4403869C2
(de)
|
1994-02-08 |
1998-01-15 |
Veitsch Radex Ag |
Feuerfester keramischer Versatz und dessen Verwendung
|
|
WO1996027604A1
(en)
|
1995-03-06 |
1996-09-12 |
Nexstar Pharmaceuticals, Inc. |
High-affinity oligonucleotide ligands to secretory phospholipase a2(spla2)
|
|
US5859228A
(en)
|
1995-05-04 |
1999-01-12 |
Nexstar Pharmaceuticals, Inc. |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
|
ES2276405T3
(es)
|
1995-06-02 |
2007-06-16 |
Gilead Sciences, Inc. |
Ligandos de oligonucleotidos de alta afinidad a pdgf.
|
|
US5723594A
(en)
|
1995-06-07 |
1998-03-03 |
Nexstar Pharmaceuticals, Inc. |
High affinity PDGF nucleic acid ligands
|
|
US6229002B1
(en)
|
1995-06-07 |
2001-05-08 |
Nexstar Pharmaceuticlas, Inc. |
Platelet derived growth factor (PDGF) nucleic acid ligand complexes
|
|
US5945527A
(en)
|
1996-05-30 |
1999-08-31 |
Nexstar Pharmaceuticals, Inc. |
Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
|
|
US6051698A
(en)
|
1997-06-06 |
2000-04-18 |
Janjic; Nebojsa |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
|
US6168788B1
(en)
|
1997-09-26 |
2001-01-02 |
Leon Wortham |
Fibrin glue without fibrinogen and biosealant compositions and methods
|
|
US20060057573A1
(en)
|
2002-02-15 |
2006-03-16 |
Somalogic, Inc |
Methods and reagents for detecting target binding by nucleic acid ligands
|
|
US20070166741A1
(en)
|
1998-12-14 |
2007-07-19 |
Somalogic, Incorporated |
Multiplexed analyses of test samples
|
|
US20030054360A1
(en)
|
1999-01-19 |
2003-03-20 |
Larry Gold |
Method and apparatus for the automated generation of nucleic acid ligands
|
|
US6312949B1
(en)
*
|
1999-03-26 |
2001-11-06 |
The Salk Institute For Biological Studies |
Regulation of tyrosine hydroxylase expression
|
|
JP2001245671A
(ja)
*
|
2000-03-07 |
2001-09-11 |
Chiba Prefecture |
ヒト神経芽細胞腫においてクローニングされた新規遺伝子及び新規遺伝子の断片
|
|
US6376190B1
(en)
|
2000-09-22 |
2002-04-23 |
Somalogic, Inc. |
Modified SELEX processes without purified protein
|
|
US6579276B2
(en)
|
2001-01-22 |
2003-06-17 |
Iomed, Inc. |
Ocular iontophoretic device and method for inhibiting vascular endothelial growth factor (VEGF) using the same
|
|
US20070082337A1
(en)
|
2004-01-27 |
2007-04-12 |
Compugen Ltd. |
Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
|
|
EP2305813A3
(en)
|
2002-11-14 |
2012-03-28 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
AU2003294437A1
(en)
|
2002-11-21 |
2004-06-18 |
Archemix Corporation |
Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
|
|
WO2006050498A2
(en)
|
2004-11-02 |
2006-05-11 |
Archemix Corp. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
JP2006516288A
(ja)
|
2003-01-21 |
2006-06-29 |
アーケミックス コーポレイション |
眼の薬物療法において有用なアプタマー治療薬
|
|
WO2004067765A2
(en)
|
2003-01-29 |
2004-08-12 |
Keck Graduate Institute |
Organism fingerprinting using nicking agents
|
|
EP1620547B1
(en)
*
|
2003-04-21 |
2014-06-18 |
Archemix LLC |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
CL2004001996A1
(es)
|
2003-08-08 |
2005-05-06 |
Eyetech Pharmaceuticals Inc |
Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
|
|
NZ592039A
(en)
|
2003-08-27 |
2013-03-28 |
Ophthotech Corp |
Combination therapy for the treatment of ocular neovascular disorders
|
|
WO2005052121A2
(en)
|
2003-11-21 |
2005-06-09 |
Archemix Corp. |
Multivalent aptamers
|
|
US8071364B2
(en)
|
2003-12-24 |
2011-12-06 |
Transgenrx, Inc. |
Gene therapy using transposon-based vectors
|
|
HUE025489T2
(en)
|
2006-01-17 |
2016-04-28 |
Somalogic Inc |
Multiplexed analysis of test samples
|
|
US7947447B2
(en)
|
2007-01-16 |
2011-05-24 |
Somalogic, Inc. |
Method for generating aptamers with improved off-rates
|
|
US20110136099A1
(en)
*
|
2007-01-16 |
2011-06-09 |
Somalogic, Inc. |
Multiplexed Analyses of Test Samples
|
|
US8975026B2
(en)
|
2007-01-16 |
2015-03-10 |
Somalogic, Inc. |
Method for generating aptamers with improved off-rates
|
|
US7855054B2
(en)
|
2007-01-16 |
2010-12-21 |
Somalogic, Inc. |
Multiplexed analyses of test samples
|
|
US7964356B2
(en)
*
|
2007-01-16 |
2011-06-21 |
Somalogic, Inc. |
Method for generating aptamers with improved off-rates
|
|
ES3045958T3
(en)
|
2007-07-17 |
2025-12-01 |
Somalogic Operating Co Inc |
Method for generating aptamers with improved off-rates
|
|
WO2010108126A2
(en)
|
2009-03-19 |
2010-09-23 |
Fate Therapeutics, Inc. |
Reprogramming compositions and methods of using the same
|
|
WO2010129666A1
(en)
|
2009-05-05 |
2010-11-11 |
Altermune Technologies, Llc |
Chemically programmable immunity
|
|
NZ598557A
(en)
|
2009-08-18 |
2013-08-30 |
Baxter Int |
Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
|
|
US8815779B2
(en)
|
2009-09-16 |
2014-08-26 |
SwitchGear Genomics, Inc. |
Transcription biomarkers of biological responses and methods
|
|
WO2011130065A1
(en)
|
2010-04-12 |
2011-10-20 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF MET GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
NZ602618A
(en)
*
|
2010-04-12 |
2013-12-20 |
Somalogic Inc |
Aptamers to beta-ngf and their use in treating beta-ngf mediated diseases and disorders
|
|
ITRM20100536A1
(it)
|
2010-10-12 |
2012-04-12 |
Consiglio Nazionale Ricerche |
Aptamero inibitore di egfr per uso in terapia e diagnosi
|
|
KR20190092590A
(ko)
|
2011-04-01 |
2019-08-07 |
아이오니스 파마수티컬즈, 인코포레이티드 |
전사 신호 전달 인자 및 활성 인자 3(stat3) 발현 조절
|
|
WO2013064702A2
(en)
*
|
2011-11-03 |
2013-05-10 |
Diagenic Asa |
Probes for diagnosis and monitoring of neurodegenerative disease
|
|
CA2868096C
(en)
*
|
2012-03-28 |
2019-12-31 |
Somalogic, Inc. |
Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
|
|
ES2834910T3
(es)
|
2013-09-09 |
2021-06-21 |
Somalogic Inc |
Aptámeros de PDGF y VEGF que tienen una estabilidad mejorada y su uso en el tratamiento de enfermedades y trastornos mediados por PDGF y VEGF
|